Latest news:
FDA Announces Shift Away from Mandatory Animal Testing – BioReperia Offers a Validated, Human-Relevant Alternative
Read more
Immune oncology

Evaluation of immunotherapies using zebrafish embryos

Our unique ZTX®platform provides a powerful in-vivo model for evaluating immunotherapies, enabling real-time imaging and insights into tumor-immune interactions.

evaluation of immunotherapies

How it works

  1. A tumor xenograft is created from fluorescent-labeled human tumor cells in zebrafish larvae.
  2. The human immune system is reconstituted by intravenous (i.v.) injection of human immune cells from patients or healthy donors.
  3. Tumor-bearing zebrafish larvae are treated with the drug candidate, such as antibodies of ADCs, for three days. Treatments can be administered to the water or injected i.v.
  4. Output shows the efficacy of treatment-induced tumor regression and inhibition of metastasis invasion.

Learn more about the ZTX®platform

Example studies

Below are examples of how the ZTX®platform has been used for immune-oncology studies.

Evaluation of

Immune check point inhibitors

Tumor xenografts (blue fluorescence) were generated from an anti-PD1-sensitive melanoma cell line. Tumor-infiltrating lymphocytes (TILs, red fluorescence) directed to recognize the melanoma cells were administered i.v. in combination with an anti-PD-1 antibody or isotype control antibody.

There was a significant tumor regression upon co-incubation with TILs and the infiltration of T-cells is increased in the presence of the anti-PD-1 antibody.

Target validation for

Multi-specific antibodies

How it works

  • Xenografts generated from Target positive and Target negative cell line
  • T cells isolated from healthy donors (injected i.v)
  • Multi-specific antibody (co-injected with the immune cells)

Output

  • Significant tumor regression with multi-specific antibody in primary tumor in target positive cells.
  • No significant target engagement was associated with the multispecific antibody in the target negative cell line.

ZTX®platform as

Companion diagnostics for autologous T-cell treatment

How it works

  • Xenografts generated from primary patient tumors (blue fluorescence).
  • T cells from the patient (red) were isolated and subsequently trained to recognize the tumors.
  • The autologous T cells were tested for their ability to kill the tumor cells by injecting them i.v. into zebrafish larvae bearing the patient´s xenograft.

Output

  • ZTX®platform is used as a companion diagnostics during the clinical trial to select and exclude patients for treatment based on the results that determine responders and non-responders to the treatment.
  • Increased use of the treatment due to the high likelihood that the patients will respond to the treatment.

This website uses cookies

We use essential cookies to make our website work. With your consent, we also use non-essential cookies to improve the user experience and analyze website traffic. You can change your cookie settings at any time by clicking on Cookie settings..

Which cookies do you want to accept?

This website uses cookies

We use different types of cookies to optimize your experience on our website. Click on the categories below to learn more about their purposes. You can choose which types of cookies to allow and can change your settings at any time. Remember that disabling cookies may affect your experience on the website.

Which cookies do you want to accept?

These cookies are essential for the proper functioning of the website and cannot be disabled.

These cookies collect information about how you use our website. All of the data is anonymized and cannot be used to identify you.

Read more about Google's privacy policy and terms of use